Deciding whether to liquidate or sell your shares of Ocugen requires a careful assessment of your individual portfolio diversification strategy, risk parameters, and original investment thesis. Because clinical-stage biopharmaceutical equities experience sharp price swings driven by clinical trial updates, regulatory decisions, and equity offerings, investors must weigh their risk comfort levels. Consulting a licensed professional financial advisor and reviewing personal financial objectives are essential steps before executing any transaction.